X4 Pharmaceuticals Inc — Liquidità Trimestrale (NASDAQ:XFOR) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 146.45 M130.01 M105.17 M163.56 M290.46 M Totale passività 124.3 M107.07 M101.2 M101.94 M104.17 M Patrimonio netto totale 22.15 M22.94 M3.97 M61.62 M186.29 M Totale passività e patrimonio netto 146.45 M130.01 M105.17 M163.56 M290.46 M Debito totale 77.66 M77.41 M77.18 M76.3 M75.99 M Indebitamento netto -24.44 M-9.59 M14.18 M-45.91 M-177.01 M

Notizie

Stifel conferma il rating su X4 Pharmaceuticals per progressi negli studi

X4 Pharmaceuticals (XFOR) Reports Q4 Loss, Tops Revenue Estimates

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

X4 Pharmaceuticals alla Leerink Global Healthcare Conference: Svolta Strategica verso l’Ematologia Rara

X4 Pharmaceuticals at Leerink Global Healthcare Conference: Strategic Shift to Rare Hematology

Guggenheim initiates X4 Pharmaceuticals stock with buy rating

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

Comitato EMA approva mavorixafor per la sindrome WHIM ultra-rara

EMA panel backs mavorixafor for ultra-rare WHIM syndrome

Vericel Corporation (VCEL) Matches Q4 Earnings Estimates

X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

X4 Pharmaceuticals al Guggenheim Summit: Focus sulla Neutropenia Cronica